The expression of the androgen receptor (AR) plays various different prognostic roles depending on the breast cancer subtype, such as the difference between ER-positive and ER-negative breast cancers with the expression levels of around 67–88% [37, 38] and 12–50% [39] for AR, respectively. This evidence concerns the gene AR and breast carcinoma.